Clinical trial
Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable…
NCT00358436 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00358436 |
|---|---|
| Title | Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD) |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Obstructive Pulmonary Disease (COPD) |
| Intervention type | Drug |
| Interventions | Aclidinium bromide, Placebo |
| Enrollment | 804 |
| Start date | Aug 1, 2006 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Jul 31, 2006 |
| Last update posted | Jan 4, 2017 |
| Countries | Argentina, Australia, Canada, Mexico, New Zealand, South Africa, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: